We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where Arcus Biosciences, Inc. (NYSE:RCUS) stands against other top insider purchases last month.
Will there be a recession? How will new tariffs impact the U.S. economy? What’s next on President Trump’s geopolitical agenda? These are some of the concerning questions influencing market conditions.
According to J.P. Morgan’s chief global economist, Bruce Kasman, there is about a 40% chance of a U.S. recession and a risk of lasting damage to the country’s reputation as an investment destination, writes Reuters.
“Where we stand now is with a heightened concern about the U.S. economy,” Kasman said to reporters in Singapore on Wednesday.
Additionally, Goldman Sachs lowered its 2025-end target for the broader market. “The proximate causes of the market decline are the jump in policy uncertainty largely related to tariffs, concerns about the economic growth outlook, and a positioning unwind, especially among hedge funds,” analysts at Goldman Sachs wrote in a Monday note.
The experts further explained that the drop in a broader market index was mostly driven by a 14% drop in the share prices of the “Magnificent 7” stocks.
As the market responds to evolving political and economic changes, some analysts remain optimistic, particularly when it comes to the growth potential of AI technology. During these times, insider trading often captures attention, as company executives have valuable insights into their organizations. For instance, when a CEO or CFO buys company stock, it can indicate a positive outlook on the business’s future.
On the other hand, insider selling isn’t necessarily a sign of a lack of confidence, as it may stem from personal financial considerations or efforts to diversify portfolios. Executives frequently execute these transactions through pre-established plans (such as 10b5-1 plans), which are designed to avoid any appearance of improper timing.
While insider activity can offer useful signals, it’s important to consider it in the context of other factors, such as the company’s financial performance, market trends, and industry developments.
Our Methodology
In this report, we’ll focus on the stocks that insiders spent the most money on in February. Using Insider Monkey’s insider trading screener, we’ve identified stocks where at least three insiders acquired shares last month. From this group, we’ve highlighted the 10 stocks with the highest value of insider purchases.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
For each stock, we provide details on the total value of insider purchases and the company’s current market capitalization. Let’s take a look at the top 10 insider purchases from last month.
A scientist in a laboratory using advanced microscopes to analyze tumor cells.
Arcus Biosciences, Inc. (NYSE:RCUS)
Total value of insider purchases in February: $15,402,661.00
Market capitalization: $1.01 billion
Arcus Biosciences is a clinical-stage biopharmaceutical company engaged in the development of best-in-class molecules and combination therapies for cancer patients. Among the company’s leading candidates are Domvanalimab, an anti-TIGIT antibody currently in Phase 2 and Phase 3 clinical trials, and AB308, an investigational anti-TIGIT monoclonal antibody in a Phase 1b clinical trial studying patients with advanced solid and hematologic malignancies. TIGIT is a checkpoint protein found on immune cells in the tumor microenvironment that inhibits the immune system’s natural ability to detect and kill cancer cells.
In February, three insiders acquired a total of $15.40 million worth of Arcus shares at an average price of $10.41 per share. Currently, the stock is trading at $9.46 per share, having lost 36.47% year-to-date, and 49.25% over the past 12 months.
Ten analysts have rated Arcus stock as “Buy” and projected a price of $30.25, according to MarketBeat. The average price target represents a forecasted upside of 219.16% from the latest price.
Overall, RCUS ranks 8th on our list of top insider purchases last month. While we acknowledge the potential of RCUS, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RCUS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. This article is originally published at Insider Monkey.
